CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Niagen® +1 moredrug
Likely dose
Niagen® 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03482167
NCT03482167Phase 2Completed
CompareCT.gov

NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

University of Delaware·interventional·Posted Mar 29, 2018·Updated Apr 4, 2025

In Brief

A Phase 2 clinical trial evaluating Niagen® and Placebo for Mild Cognitive Impairment. Completed, enrolled 64 participants across 1 site.

Detailed Summary

This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities. Overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related memory loss.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartMar 20, 2019
Primary CompletionJan 8, 2024
Study CompletionJan 22, 2024
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 8.3 years ago

Interventions

Niagen®drug

250 mg capsules (4 capsules daily)

Placeboother

placebo